Navigation Links
A Detail Analysis of Head and Neck Cancer

The discovery of the molecular mechanism behind the aggressive head and neck cancer was unveiled by the researchers at the San Francisco VA Medical Center (SFVAMC). // It is a highly malignant form of cancer with a very high death rate. They have discovered the triple interaction between CD44, hyaluronan (HA), and LARG. CD44 is a surface receptor molecule that plays an important role in a variety of cellular functions. Hyaluronan (HA) is a complex carbohydrate found in the connective tissues between cells. LARG is a signal activator found in tumor cells. The triple interaction results in the initiation of two molecular pathways that simultaneously cause tumor cell growth and tumor cell migration.

Lilly Bourguignon, PhD, a research career scientist at SFVAMC and a professor of medicine at the University of California, San Francisco is the lead author. The study results are reported In Press section of the Journal of Biological Chemistry. Bourguignon and her team found that HA mediates the interaction between CD44 and LARG in a way that stimulates a molecular pathway called RhoA. It causes the tumor cell's cytoskeleton to reorganize such that the tumor cells migrate to other sites in the body, resulting in cancer metastasis. Then the HA-mediated CD44/LARG complex binds with epidermal growth factor receptor (EGFR), located on the tumor cell's surface.

This initiates another molecular pathway called Ras which promotes the growth of the tumor cells. LARG is a central player in these molecular interactions and can be used in the potential treatment that could prevent both pathways from being initiated. Inside the LARG segment there is a PDZ domain which when introduced into the tumor cell, it binds up all available CD44 and EGFR, leaving them unavailable to initiate the deadly twin molecular pathways. In the future, LARG could be utilized as a drug target leading to a new therapeutic strategy. The CD44/EGFR complex can be used as a marker for potenti ally aggressive head-neck tumors. This complex may be used a clinical predictor for evaluating the potential of head and neck cancers to metastasize.


'"/>




Related medicine news :

1. Details Of Heart Failure Discovered
2. Details of Cosmetic Surgery in a Special Website.
3. New Zealand Requests Details from Britain about ‘Black Sheep
4. Molecular Anatomy of Influenza Virus Detailed
5. Mobile Phone and Cancer – A Detailed Study to Understand the Risk
6. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
7. Meta Analysis Links Diabetes And Colorectal Cancer
8. NASA Analysis Say 2005 Was The Warmest Year
9. First Suspected Bird Flu Case In Serbia: Samples Sent For Analysis
10. Analysis: Bowel Diseases Triples Infertility Risks In Women
11. Analysis of Placenta Helps In Diagnosis of Autism At Birth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology: